{
  "ticker": "DXB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02963316",
  "id": "02963316",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250630",
  "time": "0833",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250630/pdf/06l7h446ngkmy3.pdf",
  "summary": "- **Milestone Payment Received**: Dimerix received \u00a5400 million (~AU$4.2 million) from FUSO Pharmaceutical for initiating clinical sites in Japan.  \n- **Potential Future Payments**: Up to \u00a510.5 billion (~AU$107 million) in total milestone payments (development + sales) and 15-20% royalties on net sales from FUSO.  \n- **Total Licensing Deals**: Over AU$65 million received to date across four regional licensing agreements, with potential for ~AU$1.4 billion in total milestone payments plus royalties.  \n- **ACTION3 Trial Progress**: Japanese sites will recruit ~20 patients for FSGS Phase 3 study, supporting potential regulatory approval in Japan.  \n\n**Key Takeaways for Trading/Capital Markets**: Positive cash inflow (AU$4.2M) and confirmation of partnership progress. Upside potential from future milestones (up to AU$107M from FUSO alone). Licensing pipeline (AU$1.4B total potential) remains a material valuation driver.",
  "usage": {
    "prompt_tokens": 2113,
    "completion_tokens": 212,
    "total_tokens": 2325,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-29T22:36:31.501317"
}